Limits...
Glabridin attenuates the migratory and invasive capacity of breast cancer cells by activating microRNA-200c.

Ye X, Jiang F, Li Y, Mu J, Si L, Wang X, Ning S, Li Z - Cancer Sci. (2014)

Bottom Line: However, little is known regarding the effect of microRNA (miRNA) on GLA's anti-metastatic activity.GLA induced the mesenchymal-epithelial transition in vitro and in vivo, as determined by increased expression of the epithelial marker, E-cadherin, and decreased expression of the mesenchymal marker, vimentin.Overexpression of miR-200c enhanced the expression of E-cadherin and decreased the expression of vimentin.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Modern Toxicology, Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Nanjing Medical University, Nanjing, China.

Show MeSH

Related in: MedlinePlus

Glabridin (GLA) inhibits the migratory capacity of human breast cancer cells. (a) Effects of GLA on the viability of breast cancer cells. MDA-MB-231 and BT-549 breast cancer cells were exposed to 0.0, 5.0, 10.0 or 20.0 μM GLA for 4 days. Their viability was measured by use of a Cell Counting Kit-8 assay. The relative folds of cell viability were determined by comparing growth of cells not exposed to GLA. (b) Cells were exposed to 0.0, 5.0, 10.0 or 20.0 μM GLA for 4 days. After the cells were wounded, they were exposed to the same concentrations of GLA for another 24 h. GLA attenuated the migratory capacity of MDA-MB-231 (top) and BT-549 (bottom) cells, as determined by scratch wound-healing assays. (c) Relative levels of cell migration.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317926&req=5

fig01: Glabridin (GLA) inhibits the migratory capacity of human breast cancer cells. (a) Effects of GLA on the viability of breast cancer cells. MDA-MB-231 and BT-549 breast cancer cells were exposed to 0.0, 5.0, 10.0 or 20.0 μM GLA for 4 days. Their viability was measured by use of a Cell Counting Kit-8 assay. The relative folds of cell viability were determined by comparing growth of cells not exposed to GLA. (b) Cells were exposed to 0.0, 5.0, 10.0 or 20.0 μM GLA for 4 days. After the cells were wounded, they were exposed to the same concentrations of GLA for another 24 h. GLA attenuated the migratory capacity of MDA-MB-231 (top) and BT-549 (bottom) cells, as determined by scratch wound-healing assays. (c) Relative levels of cell migration.

Mentions: Glabridin (GLA) did not appreciably affect the vitality of MDA-MB-231 or BT-549 breast cancer cells at concentrations of 0.0, 5.0, 10.0 or 20.0 μM (Fig. 1a). To determine the effects of GLA on the motility of breast cancer cells, wound healing assays were performed. MDA-MB-231 and BT-549 cells displayed high motility, but GLA reduced such capability in a dose-dependent manner (Fig. 1b). Because 10.0 μM GLA effectively decreased the motility of these cells, this concentration was selected for further investigations. As determined with transwell assays, GLA decreased both the migratory and invasive capacities of MDA-MB-231 and BT-549 cells (Fig. 2a–c).


Glabridin attenuates the migratory and invasive capacity of breast cancer cells by activating microRNA-200c.

Ye X, Jiang F, Li Y, Mu J, Si L, Wang X, Ning S, Li Z - Cancer Sci. (2014)

Glabridin (GLA) inhibits the migratory capacity of human breast cancer cells. (a) Effects of GLA on the viability of breast cancer cells. MDA-MB-231 and BT-549 breast cancer cells were exposed to 0.0, 5.0, 10.0 or 20.0 μM GLA for 4 days. Their viability was measured by use of a Cell Counting Kit-8 assay. The relative folds of cell viability were determined by comparing growth of cells not exposed to GLA. (b) Cells were exposed to 0.0, 5.0, 10.0 or 20.0 μM GLA for 4 days. After the cells were wounded, they were exposed to the same concentrations of GLA for another 24 h. GLA attenuated the migratory capacity of MDA-MB-231 (top) and BT-549 (bottom) cells, as determined by scratch wound-healing assays. (c) Relative levels of cell migration.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317926&req=5

fig01: Glabridin (GLA) inhibits the migratory capacity of human breast cancer cells. (a) Effects of GLA on the viability of breast cancer cells. MDA-MB-231 and BT-549 breast cancer cells were exposed to 0.0, 5.0, 10.0 or 20.0 μM GLA for 4 days. Their viability was measured by use of a Cell Counting Kit-8 assay. The relative folds of cell viability were determined by comparing growth of cells not exposed to GLA. (b) Cells were exposed to 0.0, 5.0, 10.0 or 20.0 μM GLA for 4 days. After the cells were wounded, they were exposed to the same concentrations of GLA for another 24 h. GLA attenuated the migratory capacity of MDA-MB-231 (top) and BT-549 (bottom) cells, as determined by scratch wound-healing assays. (c) Relative levels of cell migration.
Mentions: Glabridin (GLA) did not appreciably affect the vitality of MDA-MB-231 or BT-549 breast cancer cells at concentrations of 0.0, 5.0, 10.0 or 20.0 μM (Fig. 1a). To determine the effects of GLA on the motility of breast cancer cells, wound healing assays were performed. MDA-MB-231 and BT-549 cells displayed high motility, but GLA reduced such capability in a dose-dependent manner (Fig. 1b). Because 10.0 μM GLA effectively decreased the motility of these cells, this concentration was selected for further investigations. As determined with transwell assays, GLA decreased both the migratory and invasive capacities of MDA-MB-231 and BT-549 cells (Fig. 2a–c).

Bottom Line: However, little is known regarding the effect of microRNA (miRNA) on GLA's anti-metastatic activity.GLA induced the mesenchymal-epithelial transition in vitro and in vivo, as determined by increased expression of the epithelial marker, E-cadherin, and decreased expression of the mesenchymal marker, vimentin.Overexpression of miR-200c enhanced the expression of E-cadherin and decreased the expression of vimentin.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Modern Toxicology, Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Nanjing Medical University, Nanjing, China.

Show MeSH
Related in: MedlinePlus